Published in Curr Opin Oncol on January 01, 2006
Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev (2008) 7.87
PI3K and cancer: lessons, challenges and opportunities. Nat Rev Drug Discov (2014) 4.81
De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes. Nat Genet (2012) 4.51
Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell (2015) 4.16
Helical domain and kinase domain mutations in p110alpha of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc Natl Acad Sci U S A (2008) 3.99
Class I PI3K in oncogenic cellular transformation. Oncogene (2008) 3.90
Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res (2009) 3.59
PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR. J Clin Invest (2007) 3.54
Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER+ breast cancer. Breast Cancer Res (2010) 3.53
PIK3CA mutations and copy number gains in human lung cancers. Cancer Res (2008) 3.42
Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents. J Cell Biol (2008) 3.36
Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev (2009) 3.35
Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor. Nat Med (2010) 3.26
Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem Res (2006) 3.12
SOX2 is an oncogene activated by recurrent 3q26.3 amplifications in human lung squamous cell carcinomas. PLoS One (2010) 2.21
Comprehensive dissection of PDGF-PDGFR signaling pathways in PDGFR genetically defined cells. PLoS One (2008) 2.10
Anchorage-independent cell growth signature identifies tumors with metastatic potential. Oncogene (2009) 1.99
FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One (2010) 1.97
Direct positive regulation of PTEN by the p85 subunit of phosphatidylinositol 3-kinase. Proc Natl Acad Sci U S A (2010) 1.83
The role of the PTEN/AKT Pathway in NOTCH1-induced leukemia. Cell Cycle (2008) 1.83
MiR-34a/c-Dependent PDGFR-α/β Downregulation Inhibits Tumorigenesis and Enhances TRAIL-Induced Apoptosis in Lung Cancer. PLoS One (2013) 1.82
PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances. Biochem J (2012) 1.56
Phosphoinositide 3-kinase signaling pathway mediated by p110α regulates invadopodia formation. J Cell Biol (2011) 1.56
Cancer-derived mutations in the regulatory subunit p85alpha of phosphoinositide 3-kinase function through the catalytic subunit p110alpha. Proc Natl Acad Sci U S A (2010) 1.55
PTEN, stem cells, and cancer stem cells. J Biol Chem (2008) 1.52
PIK3CA mutations in in situ and invasive breast carcinomas. Cancer Res (2010) 1.49
The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer. Br J Cancer (2013) 1.33
Breast cancer antiestrogen resistance-3 expression regulates breast cancer cell migration through promotion of p130Cas membrane localization and membrane ruffling. Cancer Res (2007) 1.33
Targeting the phosphatidylinositol 3-kinase signaling pathway in breast cancer. Oncologist (2011) 1.32
Overcoming resistance to tyrosine kinase inhibitors: lessons learned from cancer cells treated with EGFR antagonists. Cell Cycle (2009) 1.29
Oncogenic NOTCH1 control of MYC and PI3K: challenges and opportunities for anti-NOTCH1 therapy in T-cell acute lymphoblastic leukemias and lymphomas. Clin Cancer Res (2008) 1.27
Targeting mTOR for the treatment of AML. New agents and new directions. Oncotarget (2011) 1.26
Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer. Cancer Metastasis Rev (2009) 1.26
DNA sequence profiles of the colorectal cancer critical gene set KRAS-BRAF-PIK3CA-PTEN-TP53 related to age at disease onset. PLoS One (2010) 1.26
Novel somatic mutations to PI3K pathway genes in metastatic melanoma. PLoS One (2012) 1.21
Combined experimental and computational analysis of DNA damage signaling reveals context-dependent roles for Erk in apoptosis and G1/S arrest after genotoxic stress. Mol Syst Biol (2012) 1.20
Highly frequent promoter methylation and PIK3CA amplification in non-small cell lung cancer (NSCLC). BMC Cancer (2011) 1.19
The insulin-like growth factor-I-mTOR signaling pathway induces the mitochondrial pyrimidine nucleotide carrier to promote cell growth. Mol Biol Cell (2007) 1.16
Activation of the PI3K/AKT pathway induces urothelial carcinoma of the renal pelvis: identification in human tumors and confirmation in animal models. Cancer Res (2009) 1.15
Trastuzumab anti-tumor efficacy in patient-derived esophageal squamous cell carcinoma xenograft (PDECX) mouse models. J Transl Med (2012) 1.11
Diosgenin, a steroidal saponin, inhibits migration and invasion of human prostate cancer PC-3 cells by reducing matrix metalloproteinases expression. PLoS One (2011) 1.10
The sensors and regulators of cell-matrix surveillance in anoikis resistance of tumors. Int J Cancer (2010) 1.08
Update on anaplastic thyroid carcinoma: morphological, molecular, and genetic features of the most aggressive thyroid cancer. Int J Endocrinol (2014) 1.07
PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup. PLoS One (2014) 1.07
Genistein inhibits proliferation of colon cancer cells by attenuating a negative effect of epidermal growth factor on tumor suppressor FOXO3 activity. BMC Cancer (2011) 1.06
Combined expression of caveolin-1 and an activated AKT/mTOR pathway predicts reduced disease-free survival in clinically confined renal cell carcinoma. Br J Cancer (2008) 1.06
PI-3K/Akt pathway-dependent cyclin D1 expression is responsible for arsenite-induced human keratinocyte transformation. Environ Health Perspect (2008) 1.06
Autophagic pathways as new targets for cancer drug development. Acta Pharmacol Sin (2010) 1.05
Normal development is an integral part of tumorigenesis in T cell-specific PTEN-deficient mice. Proc Natl Acad Sci U S A (2008) 1.04
PIKing the right isoform: the emergent role of the p110beta subunit in breast cancer. Virchows Arch (2010) 1.01
Apocrine-eccrine carcinomas: molecular and immunohistochemical analyses. PLoS One (2012) 1.01
Impact of heat-shock protein 90 on cancer metastasis. Future Oncol (2009) 1.00
AKT-independent PI3-K signaling in cancer - emerging role for SGK3. Cancer Manag Res (2013) 0.99
Using tandem mass spectrometry in targeted mode to identify activators of class IA PI3K in cancer. Cancer Res (2011) 0.98
A novel MMP-2 inhibitor 3-azidowithaferin A (3-azidoWA) abrogates cancer cell invasion and angiogenesis by modulating extracellular Par-4. PLoS One (2012) 0.98
Integrin/Fak/Src-mediated regulation of cell survival and anoikis in human intestinal epithelial crypt cells: selective engagement and roles of PI3-K isoform complexes. Apoptosis (2012) 0.97
Enhanced antitumorigenic effects in glioblastoma on double targeting of pleiotrophin and its receptor ALK. Neoplasia (2009) 0.97
PI3K expression and PIK3CA mutations are related to colorectal cancer metastases. World J Gastroenterol (2012) 0.97
PI3K/Akt/mTOR inhibitors in breast cancer. Cancer Biol Med (2015) 0.96
A phosphoinositide 3-kinase (PI3K)-serum- and glucocorticoid-inducible kinase 1 (SGK1) pathway promotes Kv7.1 channel surface expression by inhibiting Nedd4-2 protein. J Biol Chem (2013) 0.95
Present and Future of EGFR Inhibitors for Head and Neck Squamous Cell Cancer. J Oncol (2012) 0.95
AKT hyper-phosphorylation associated with PI3K mutations in lymphatic endothelial cells from a patient with lymphatic malformation. Angiogenesis (2014) 0.94
Addition of N-terminal peptide sequences activates the oncogenic and signaling potentials of the catalytic subunit p110α of phosphoinositide-3-kinase. Cell Cycle (2011) 0.93
Synthetic oleanane triterpenoid, CDDO-Me, induces apoptosis in ovarian cancer cells by inhibiting prosurvival AKT/NF-κB/mTOR signaling. Anticancer Res (2011) 0.93
Interactome mapping of the phosphatidylinositol 3-kinase-mammalian target of rapamycin pathway identifies deformed epidermal autoregulatory factor-1 as a new glycogen synthase kinase-3 interactor. Mol Cell Proteomics (2010) 0.92
PRK1 distribution in normal tissues and carcinomas: overexpression and activation in ovarian serous carcinoma. Hum Pathol (2009) 0.92
Dp44mT targets the AKT, TGF-β and ERK pathways via the metastasis suppressor NDRG1 in normal prostate epithelial cells and prostate cancer cells. Br J Cancer (2013) 0.92
Anti-apoptotic effects of suppressor of cytokine signaling 3 and 1 in psoriasis. Cell Death Dis (2012) 0.92
Targeting cancer by binding iron: Dissecting cellular signaling pathways. Oncotarget (2015) 0.91
PIK3CA exon 20 mutations are associated with poor prognosis in breast cancer patients. Clinics (Sao Paulo) (2012) 0.91
Targeted therapies for ER+/HER2- metastatic breast cancer. BMC Med (2015) 0.91
Profiling of phospho-AKT, phospho-mTOR, phospho-MAPK and EGFR in non-small cell lung cancer. J Histochem Cytochem (2014) 0.90
Identification of a role for the PI3K/AKT/mTOR signaling pathway in innate immune cells. PLoS One (2014) 0.89
The determinants of head and neck cancer: Unmasking the PI3K pathway mutations. J Carcinog Mutagen (2013) 0.89
Antiproliferative effect of a novel mTOR inhibitor temsirolimus contributes to the prolonged survival of orthotopic esophageal cancer-bearing mice. Cancer Biol Ther (2013) 0.88
The favorable impact of PIK3CA mutations on survival: an analysis of 2587 patients with breast cancer. Chin J Cancer (2012) 0.88
PIK3CA and PIK3CB expression and relationship with multidrug resistance in colorectal carcinoma. Int J Clin Exp Pathol (2014) 0.88
Inhibition of Akt with small molecules and biologics: historical perspective and current status of the patent landscape. Expert Opin Ther Pat (2011) 0.87
Reviving Lonidamine and 6-Diazo-5-oxo-L-norleucine to Be Used in Combination for Metabolic Cancer Therapy. Biomed Res Int (2015) 0.85
Multiple metabolic alterations exist in mutant PI3K cancers, but only glucose is essential as a nutrient source. PLoS One (2012) 0.85
Phosphatidylinositol 3-kinase-dependent activation of mammalian protein kinase B/Akt in Saccharomyces cerevisiae, an in vivo model for the functional study of Akt mutations. J Biol Chem (2009) 0.85
A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer. Oral Oncol (2015) 0.85
PIK3CA gene mutations and overexpression: implications for prognostic biomarker and therapeutic target in Chinese esophageal squamous cell carcinoma. PLoS One (2014) 0.84
PI3K/Akt and GSK-3β prevents in a differential fashion the malignant phenotype of colorectal cancer cells. J Cancer Res Clin Oncol (2010) 0.84
A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours. Br J Cancer (2013) 0.84
Fresh surgical specimens yield breast stem/progenitor cells and reveal their oncogenic abnormalities. Ann Surg Oncol (2011) 0.83
Cyclin D1 induction by benzo[a]pyrene-7,8-diol-9,10-epoxide via the phosphatidylinositol 3-kinase/Akt/MAPK- and p70s6k-dependent pathway promotes cell transformation and tumorigenesis. J Biol Chem (2009) 0.83
Relative quantification of PIK3CA gene expression level in fine-needle aspiration biopsy thyroid specimens collected from patients with papillary thyroid carcinoma and non-toxic goitre by real-time RT-PCR. Thyroid Res (2010) 0.83
Evidence for PTEN-independent Akt activation and Akt-independent p27(Kip1) expression in advanced bladder cancer. Oncol Lett (2011) 0.82
Membrane Recruitment as a Cancer Mechanism: A Case Study of Akt PH Domain. Cellscience (2007) 0.82
Targeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine? World J Gastroenterol (2015) 0.82
Evaluation of variation in the phosphoinositide-3-kinase catalytic subunit alpha oncogene and breast cancer risk. Br J Cancer (2011) 0.81
PIK3CA gene mutation associated with poor prognosis of lung adenocarcinoma. Onco Targets Ther (2013) 0.81
Targeted Therapies for Brain Metastases from Breast Cancer. Int J Mol Sci (2016) 0.80
Anticancer activity of pristimerin in ovarian carcinoma cells is mediated through the inhibition of prosurvival Akt/NF-κB/mTOR signaling. J Exp Ther Oncol (2014) 0.80
Smurf2 E3 ubiquitin ligase modulates proliferation and invasiveness of breast cancer cells in a CNKSR2 dependent manner. Cell Div (2014) 0.80
Dissecting the PI3K Signaling Axis in Pediatric Solid Tumors: Novel Targets for Clinical Integration. Front Oncol (2013) 0.79
Genomic characterization of esophageal squamous cell carcinoma: Insights from next-generation sequencing. World J Gastroenterol (2016) 0.79
Targeting Glutamatergic Signaling and the PI3 Kinase Pathway to Halt Melanoma Progression. Transl Oncol (2015) 0.79
NOV-002, A Glutathione Disulfide Mimetic, Suppresses Tumor Cell Invasion and Metastasis. J Carcinog Mutagen (2013) 0.79